Progress on diagnosis and treatment of drug-resistant tuberculosis in line with World Health Organization recommendations in six priority countries in the Western Pacific Region
Authors:
Open Access
- 7 November 2022
- journal article
- research article
- Published by World Health Organization, Western Pacific Regional Office in Western Pacific Surveillance and Response Journal
- Vol. 13 (4) , 12-23
Abstract
Background: Diagnosis and treatment of drug-resistant tuberculosis (DR-TB) have radically changed in accordance with recommendations from the World Health Organization (WHO) in the past decade, allowing rapid and simple diagnosis and shorter treatment duration with new and repurposed drugs. Methods: A descriptive analysis of the status and progress of DR-TB diagnosis and treatment in six priority countries in the Western Pacific Region was conducted using information from interviews with countries and the WHO TB database. Results: Over the past decade, the use of Xpert MTB/RIF has increased in the six priority countries, in parallel with implementation of national policies and algorithms to use Xpert MTB/RIF as an initial diagnostic test for TB and detection of rifampicin resistance. This has resulted in increases in the number of people diagnosed with multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB). Shorter treatment regimens with new and repurposed drugs have also been adopted for MDR/RR-TB cases, alongside a decentralized model of care, leading to improved treatment outcomes. Discussion: The Western Pacific Region has achieved considerable progress in the diagnosis and treatment of DR-TB, in line with the evolving WHO recommendations in the past decade. The continued commitment of Member States is needed to address remaining challenges, such as the impact of the coronavirus disease pandemic, suboptimal management and health system issues.Keywords
This publication has 9 references indexed in Scilit:
- The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventionsThe Lancet Respiratory Medicine, 2022
- Epidemiology of tuberculosis in the Western Pacific Region: Progress towards the 2020 milestones of the End TB StrategyWestern Pacific Surveillance and Response Journal, 2020
- The impact of COVID-19 and the restoration of tuberculosis services in the Western Pacific RegionEuropean Respiratory Journal, 2020
- WHO consolidated guidelines on tuberculosis: Module 4: Treatment - Drug-resistant tuberculosis treatment2020
- Performance-based technical support for drug-resistant TB responses: lessons from the Green Light CommitteeThe International Journal of Tuberculosis and Lung Disease, 2020
- WHO consolidated guidelines on drug-resistant tuberculosis treatment2019
- The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosisThe Lancet Respiratory Medicine, 2017
- Western Pacific Regional Green Light Committee: progress and way forwardInternational Journal of Infectious Diseases, 2015
- Automated Real-Time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF Assay for the Diagnosis of Pulmonary and Extrapulmonary TB in Adults and Children: Policy Update2013